KUALA LUMPUR, July 11 (Bernama) -- A randomised clinical trial was conducted on 120 women aged 18 to 37 years with polycystic ovarian syndrome (PCOS) that underwent biphasic in vitro maturation (CAPA-IVM) at a tertiary in vitro fertilisation (IVF) centre, Ho Chi Minh City, Vietnam, between January and June 2023.
Prof Dr Lan Vuong from the University of Medicine and Pharmacy at Ho Chi Minh City and MyDuc Hospital, who led the study, said this randomised controlled trial with 120 patients proves that CAPA-IVM without recombinant FSH (rFSH) priming is as effective as two days of rFSH priming.
“With a live birth rate of 38 per cent for single blastocyst transfer CAPA-IVM achieved a similar live birth rate than standard IVF with eight to 10 days of rFSH treatment. This is great news and a milestone achievement.
“The data supports our belief that women with PCOS are suitable for a complete gonadotrophin free, alternative fertility treatment,” she said in a statement.
After providing written informed consent, participants were randomised one-to-one ratio (1:1) to undergo CAPA-IVM with or without follicle-stimulating hormone (FSH-priming).
Participants in the FSH-priming group received two days of rFSH injections before oocyte pick-up; no rFSH was given in the non-FSH group. All retrieved cumulus oocyte complexes underwent CAPA-IVM, while matured oocytes underwent fertilisation through intracytoplasmic sperm injection (ICSI) procedure, and were cultured to blastocyst stage followed by vitrification.
Participants underwent a single blastocyst transfer during a frozen replacement cycle. The primary endpoint was the number of matured oocytes.
The study results were presented by Dr Tuong M Ho at the 40th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) on July 9 in Amsterdam, the Netherlands and have been submitted for publication in a leading reproductive medicine journal.
CAPA-IVM is a patient-friendly assisted reproductive technology method that may become an alternative option to conventional ovarian stimulation and IVF, with reduced treatment burden in some selected groups of patients.
The worldwide rights to the CAPA-IVM technology are owned by Lavima Fertility Inc. The company is developing a medical device for future application of this technology.
-- BERNAMA
No comments:
Post a Comment